[1]孔祥忍,毛双双,刘欣宇,等.新型佐剂-细菌样颗粒对百日咳抗原体液免疫的效果研究[J].医学信息,2021,34(02):95-97,104.[doi:10.3969/j.issn.1006-1959.2021.02.025]
　KONG Xiang-ren,MAO Shuang-shuang,LIU Xin-yu,et al.Study on the Effect of New Adjuvant-bacteria-like Particles on Pertussis Antigen Humoral Immunity[J].Medical Information,2021,34(02):95-97,104.[doi:10.3969/j.issn.1006-1959.2021.02.025]
点击复制

新型佐剂-细菌样颗粒对百日咳抗原体液免疫的效果研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年02期
页码:
95-97,104
栏目:
论著
出版日期:
2021-01-15

文章信息/Info

Title:
Study on the Effect of New Adjuvant-bacteria-like Particles on Pertussis Antigen Humoral Immunity
文章编号:
1006-1959（2021）02-0095-04
作者:
孔祥忍; 毛双双; 刘欣宇; 等
（山东第一医科大学，山东 泰安 271000）
Author(s):
KONG Xiang-ren; MAO Shuang-shuang; LIU Xin-yu; et al.
(Shandong First Medical University,Tai’an 271000,Shandong,China)
关键词:
细菌样颗粒; 佐剂; 百日咳; 疫苗; 体液免疫
Keywords:
Bacterial-like particles; Adjuvant; Pertussis; Vaccine; Humoral immunity
分类号:
R183.3
DOI:
10.3969/j.issn.1006-1959.2021.02.025
文献标志码:
A
摘要:
目的 探讨新型佐剂-细菌样颗粒（BLP）用于百日咳疫苗的效果。方法 将乳酸菌经三氯乙酸处理制备BLP，随机将50只小鼠分为空白对照组、BLP黏膜组、铝佐剂黏膜组、BLP佐剂腹腔组和铝佐剂腹腔组，于第0天和28天进行免疫，观察小鼠有无不良反应；在初次免疫后的第7、21及35天取血，通过ELISA检测抗百日咳毒素IgG抗体水平，ELISA检测鼻灌洗液抗百日咳毒素sIgA水平，鼻腔菌液攻击实验及肺组织病理评分分析疫苗的保护作用。结果 ①接种后各组小鼠均未发现明显异常，无体重减轻，鼻孔及口腔处均无明显炎症、溃疡及脱毛现象；②接种7、21、35天，BLP黏膜组、铝佐剂黏膜组、BLP佐剂腹腔组和铝佐剂腹腔组抗百日咳毒素IgG均高于空白对照组，且BLP佐剂腹腔组、铝佐剂腹腔组高于BLP黏膜组、铝佐剂黏膜组，差异均有统计学意义（P＜0.05），其中铝佐剂腹腔组抗体水平最高；③与空白对照组比较，各组sIgA水平均升高，BLP佐剂黏膜组sIgA水平最高，高于铝佐剂黏膜组、BLP佐剂腹腔组及铝佐剂腹腔组，差异均有统计学意义（P＜0.05）；④空白对照组表现为病理组织损伤，其他各组只出现轻微的炎性细胞浸润，其中BLP佐剂黏膜组小鼠肺组织损伤最小。结论 新型佐剂-细菌样颗粒通过黏膜免疫保护作用最佳，主要通过诱导产生高滴度的sIgA发挥作用。
Abstract:
Objective To explore the effect of a new adjuvant-bacteria-like particles (BLP) used in pertussis vaccine.Methods Lactic acid bacteria were treated with trichloroacetic acid to prepare BLP. 50 mice were randomly divided into blank control group, BLP mucosal group, aluminum adjuvant mucosal group, BLP adjuvant intraperitoneal group and aluminum adjuvant intraperitoneal group.Immunization was performed on days 0 and 28 to observe whether the mice had adverse reactions; blood was collected on days 7, 21 and 35 after the initial immunization, and the level of anti-pertussis toxin IgG antibody was detected by ELISA.ELISA detects the anti-pertussis toxin sIgA level of nasal lavage fluid,nasal cavity bacteria fluid challenge experiment and lung tissue pathological score analysis of the protective effect of the vaccine.Results ①After the inoculation, no obvious abnormalities were found in each group of mice, no weight loss, no obvious inflammation, ulcers and hair loss in the nostrils and mouth;②At 7, 21, and 35 days of vaccination, the anti-pertussis toxin IgG in the BLP mucosal group, aluminum adjuvant mucosal group, BLP adjuvant intraperitoneal group and aluminum adjuvant intraperitoneal group were higher than those of the blank control group and the BLP adjuvant intraperitoneal group and aluminum adjuvant intraperitoneal group were higher than the BLP mucosal group and aluminum adjuvant mucosal group, the difference was statistically significant (P<0.05), and the aluminum adjuvant intraperitoneal group had the highest antibody level;③Compared with the blank control group, the sIgA level of each group was increased. The BLP adjuvant mucosal group had the highest sIgA level, which was higher than that of the aluminum adjuvant mucosal group, the BLP adjuvant intraperitoneal group and the aluminum adjuvant intraperitoneal group,the differences were statistically significant(P＜0.05);④The blank control group showed pathological tissue damage, and the other groups showed only slight inflammatory cell infiltration. Among them, the BLP adjuvant mucosa group had the least lung tissue damage.Conclusion The new adjuvant-bacteria-like particles have the best protective effect through mucosal immunity, mainly by inducing high titer sIgA.

参考文献/References:

[1]Margaryan S,Wells M,Apresyan H,et al.When will the coughing stop? Characteristics of children with pertussis(whooping cough)in Armenia(2014-2018)[J].J Infect Dev Ctries,2019,13(5.1):57S-62S. [2]Li B,Chen X,Yu J,et al.Protection elicited by nasal immunization with pneumococcal surface protein A(PspA)adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice[J].Microb Pathog,2018(123):115-119. [3]Keijzer C,Haijema BJ,Meijerhof T,et al.Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion[J].Vaccine,2014,32(24):2904-2910. [4]Van Braeckel-Budimir N,Haijema BJ,Leenhouts K.Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications[J].Front Immunol,2013(4):282. [5]Moyer TJ,Kato Y,Abraham W,et al.Author Correction:A Engineered immunogen binding to alum adjuvant enhances humoral immunity[J].Nat Med,2020,26(5):804. [6]Heine SJ,Franco-Mahecha OL,Chen X,et al.lactis bacterium-like particles induce protective immunity in adult and infant mice[J].Immunol Cell Biol,2015,93(7):641-652. [7]Anyiwe K,Richardson M,Brophy J,et al.Assessing adolescent immunization options for pertussis in Canada:A cost-utility analysis[J].Vaccine,2020,38(7):1825-1833. [8]Mack I,Erlanger TE,Lang P,et al.Dose-dependent effectiveness of acellular pertussis vaccine in infants:A population-based case-control study[J].Vaccine,2020,38(6):1444-1449. [9]Raya Tonetti F,Arce L,Salva S,et al.Immunomodulatory Properties of Bacterium-Like Particles Obtained From Immunobiotic Lactobacilli:Prospects for Their Use as Mucosal Adjuvants[J].Front Immunol,2020(11):15. [10]Kye YC,Park SM,Shim BS,et al.Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection[J].ActaBiomater,2019(90):362-372.

更新日期/Last Update: 1900-01-01